Last reviewed · How we verify
ropinirole monotherapy
ropinirole monotherapy is a Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved.
Ropinirole is a small molecule that acts as a D2-like dopamine receptor agonist. It is used as monotherapy to treat Parkinson Disease, as indicated by ClinicalTrials.gov.
At a glance
| Generic name | ropinirole monotherapy |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD) (PHASE2)
- A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease (PHASE4)
- REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ropinirole monotherapy CI brief — competitive landscape report
- ropinirole monotherapy updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about ropinirole monotherapy
What is ropinirole monotherapy?
ropinirole monotherapy is a Small molecule drug developed by GlaxoSmithKline.
Who makes ropinirole monotherapy?
ropinirole monotherapy is developed and marketed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is ropinirole monotherapy in?
ropinirole monotherapy is FDA-approved (marketed).
Related
- Manufacturer: GlaxoSmithKline — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing